TG Therapeutics stock
TGTXNASDAQTG Therapeutics, Inc., HealthcareISIN US88322Q1085
65Score 65 out of 100, Neutral
Price and trend
81 / 100
Price history
+111% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 46% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 78).
The price is at its 52-week high. Largest decline in 17 years: 100% (May 2010 to December 2011).
Chart figures for advanced users
- SMA 50$56.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$45.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)78
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.94
- The lowest closing price of the last twelve months.
- Resistance$65.76
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- TG Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $10.07B, is number 38 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $616.29M (up 87.3% year on year) and earnings of $447.18M (up 1,812.4%).
- For fiscal 2026, analysts expect on average revenue of $960.01M (up 55.8%) and adjusted earnings per share of $1.00 (down 63.9%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 219 of 714 in Healthcare, median 53.
- The P/E is 96.7 (Biotechnology median 21.3, own median of recent years 188.1).
- Our model puts fair value at $41.31, with the price 59% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 426.7% a year since 2020, Biotechnology median 19.7%.Growth 70
- Analysts expect strong earnings growthUp 59.5% a year through 2028 (estimates from 6 analysts).Growth 70
- High return on capitalReturn on invested capital 26.5% in fiscal 2025, Biotechnology median −24.3%.Profitability 81
Weaknesses
- DilutionShare count up 25% since 2020.Capital allocation 51
- High debtDebt 1.32 times equity (latest quarter), Biotechnology median 0.09.Stability 57
- Volatile share priceVolatility 46% a year over the last 12 months.Stability 57
Its standout strengths are momentum and profitability, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $29.51 and expensive above $68.86 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $68.15 (cash-flow model) and $14.48 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $35.33, at 8.5% it would be $49.91.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 68.8% on the twelve months before. Revenue turned from negative at the start of the period to positive ($616.29M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 84%, operating 20%, net 73%. Last 12 months: net 12%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 9 Nov 2026EPS reported $0.35 (expected $0.36)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.000.0%
- Revenue
- $960.01M0.0%
- Earnings per share
- $2.870.0%
- Revenue
- $1.32B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −6.3%2026 guidance raised for the second time: US BRIUMVI net revenue of $890 million to $905 million and about $950 million of global revenue.
“BRIUMVI net revenue guidance to $890 million to $905 million and now expect approximately $950 million in total global revenue for 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $274,800 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Charney Laurence NSale
10 Sept 2026, Board
- Shares
- 5,000
- Price
- $54.96
- Value
- $274,800
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at TG Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- VaxcytePCVX $10.8B46
- Akeso9926.HK $10.58B32
- Sichuan Kelun Pharmaceutical002422.SZ $10.43B70
- Spyre TherapeuticsSYRE $10.14B48
- Genscript Biotech1548.HK $9.96B48
- Haisco Pharmaceutical Group002653.SZ $9.92B68
- Praxis Precision MedicinesPRAX $9.67B42
- Alteogen196170.KQ $9.56B57
ETFs that hold TG Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.79% | 0.40% | €1.49B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.49% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.44% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.31% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.31% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.13% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.09% | 0.35% | €434.1M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.09% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.